CytomX Therapeutics (CTMX) Enterprise Value (2016 - 2025)
CytomX Therapeutics' Enterprise Value history spans 12 years, with the latest figure at -$137.1 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 36.2% year-over-year to -$137.1 million; the TTM value through Dec 2025 reached -$137.1 million, down 36.2%, while the annual FY2025 figure was -$137.1 million, 36.2% down from the prior year.
- Enterprise Value reached -$137.1 million in Q4 2025 per CTMX's latest filing, up from -$143.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$79.9 million in Q1 2025 to a low of -$393.8 million in Q1 2021.
- Average Enterprise Value over 5 years is -$192.9 million, with a median of -$187.3 million recorded in 2022.
- Peak YoY movement for Enterprise Value: plummeted 58.84% in 2021, then skyrocketed 46.84% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$305.2 million in 2021, then surged by 36.56% to -$193.6 million in 2022, then grew by 9.88% to -$174.5 million in 2023, then surged by 42.34% to -$100.6 million in 2024, then plummeted by 36.2% to -$137.1 million in 2025.
- Per Business Quant, the three most recent readings for CTMX's Enterprise Value are -$137.1 million (Q4 2025), -$143.6 million (Q3 2025), and -$158.1 million (Q2 2025).